Opioid Cos. Defied FDA Promo Limits, Ex-Commissioner Says
A former FDA head told a New York jury that drugmakers strategized in the 2000s to promote opioids for uses and markets far beyond those approved, a corporate practice that threatened...To view the full article, register now.
Already a subscriber? Click here to view full article